Showing results (1-10 of 63) with videos related to
Sort By:
Pageof 7
Current Oncology (Toronto, Ont.)|April 20, 2012
A personalized approach to treatment: use of EGFR tyrosine kinase inhibitors for the treatment of non-small-cell lung cancer in CanadaV Hirsh, B Melosky, G Goss, et al.Current Oncology (Toronto, Ont.)|March 12, 2019
Perspectives on treatment advances for stage III locally advanced unresectable non-small-cell lung cancerP K Cheema, J Rothenstein, B Melosky, et al.Current Oncology (Toronto, Ont.)|June 19, 2018
Advanced typical and atypical carcinoid tumours of the lung: management recommendationsB MeloskyCurrent Oncology (Toronto, Ont.)|July 13, 2012
Supportive care treatments for toxicities of anti-egfr and other targeted agentsB MeloskyCurrent Oncology (Toronto, Ont.)|June 19, 2018
Rapidly changing treatment algorithms for metastatic nonsquamous non-small-cell lung cancerB MeloskyCancer Treatment Reviews|March 24, 2018
Breaking the biomarker code: PD-L1 expression and checkpoint inhibition in advanced NSCLCB Melosky, Q Chu, R A Juergens, et al.Current Oncology (Toronto, Ont.)|February 14, 2012
Response to second-line erlotinib in an EGFR mutation-negative patient with non-small-cell lung cancer: make no assumptionsI Karam, B MeloskyCurrent Oncology (Toronto, Ont.)|December 17, 2008
Retrospective practice review of treatment of metastatic non-small-cell lung cancer with second-line erlotinibB Melosky, J Agulnik, H AssiCurrent Oncology (Toronto, Ont.)|April 21, 2010
Systemic therapies in metastatic non-small-cell lung cancer with emphasis on targeted therapies: the rational approachV HirshCurrent Oncology (Toronto, Ont.)|February 21, 2009
The role of the epidermal growth factor receptor tyrosine kinase inhibitors as therapy for advanced, metastatic, and recurrent non-small-cell lung cancer: a Canadian national consensus statementP M Ellis, W Morzycki, B Melosky, et al.Pageof 7